» Articles » PMID: 35326546

Phenotypic and Histological Distribution Analysis Identify Mast Cell Heterogeneity in Non-Small Cell Lung Cancer

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2022 Mar 25
PMID 35326546
Authors
Affiliations
Soon will be listed here.
Abstract

Mast cells (MCs) are multifaceted innate immune cells often present in the tumor microenvironment (TME). However, MCs have been only barely characterized in studies focusing on global immune infiltrate phenotyping. Consequently, their role in cancer is still poorly understood. Furthermore, their prognosis value is confusing since MCs have been associated with good and bad (or both) prognosis depending on the cancer type. In this pilot study performed on a surgical cohort of 48 patients with Non-Small Cell Lung Cancer (NSCLC), we characterized MC population within the TME and in matching non-lesional lung areas, by multicolor flow cytometry and confocal microscopy. Our results showed that tumor-associated MCs (TAMCs) harbor a distinct phenotype as compared with MCs present in non-lesional counterpart of the lung. Moreover, we found two TAMCs subsets based on the expression of CD103 (also named alphaE integrin). CD103 TAMCs appeared more mature, more prone to interact with CD4 T cells, and located closer to cancer cells than their CD103 counterpart. In spite of these characteristics, we did not observe a prognosis advantage of a high frequency of CD103 TAMCs, while a high frequency of total TAMC correlated with better overall survival and progression free survival. Together, this study reveals that TAMCs constitute a heterogeneous population and indicates that MC subsets should be considered for patients' stratification and management in future research.

Citing Articles

The regulatory role and mechanism of mast cells in tumor microenvironment.

Ligan C, Ma X, Zhao S, Zhao W Am J Cancer Res. 2024; 14(1):1-15.

PMID: 38323271 PMC: 10839313.


Mast cells in colorectal cancer tumour progression, angiogenesis, and lymphangiogenesis.

Liu X, Li X, Wei H, Liu Y, Li N Front Immunol. 2023; 14:1209056.

PMID: 37497234 PMC: 10366593. DOI: 10.3389/fimmu.2023.1209056.


Identification of m7G-Related miRNA Signatures Associated with Prognosis, Oxidative Stress, and Immune Landscape in Lung Adenocarcinoma.

Jiang S, Xiao M, Shi Y, Wang Y, Xu Z, Wang K Biomedicines. 2023; 11(6).

PMID: 37371664 PMC: 10295992. DOI: 10.3390/biomedicines11061569.


Breaking the Invisible Barriers: Unleashing the Full Potential of Immune Checkpoint Inhibitors in Oncogene-Driven Lung Adenocarcinoma.

Kwok H, Yang J, Lam D Cancers (Basel). 2023; 15(10).

PMID: 37345086 PMC: 10216227. DOI: 10.3390/cancers15102749.


Mast cell marker gene signature: prognosis and immunotherapy response prediction in lung adenocarcinoma through integrated scRNA-seq and bulk RNA-seq.

Zhang P, Liu J, Pei S, Wu D, Xie J, Liu J Front Immunol. 2023; 14:1189520.

PMID: 37256127 PMC: 10225553. DOI: 10.3389/fimmu.2023.1189520.


References
1.
Melo F, Martin S, Sommerhoff C, Pejler G . Exosome-mediated uptake of mast cell tryptase into the nucleus of melanoma cells: a novel axis for regulating tumor cell proliferation and gene expression. Cell Death Dis. 2019; 10(9):659. PMC: 6736983. DOI: 10.1038/s41419-019-1879-4. View

2.
Atiakshin D, Samoilova V, Buchwalow I, Tiemann M . Expression of CD38 in Mast Cells: Cytological and Histotopographic Features. Cells. 2021; 10(10). PMC: 8534017. DOI: 10.3390/cells10102511. View

3.
Tomita M, Matsuzaki Y, Onitsuka T . Correlation between mast cells and survival rates in patients with pulmonary adenocarcinoma. Lung Cancer. 1999; 26(2):103-8. DOI: 10.1016/s0169-5002(99)00076-8. View

4.
Tataroglu C, Kargi A, Ozkal S, Esrefoglu N, Akkoclu A . Association of macrophages, mast cells and eosinophil leukocytes with angiogenesis and tumor stage in non-small cell lung carcinomas (NSCLC). Lung Cancer. 2003; 43(1):47-54. DOI: 10.1016/j.lungcan.2003.08.013. View

5.
Domagala M, Laplagne C, Leveque E, Laurent C, Fournie J, Espinosa E . Cancer Cells Resistance Shaping by Tumor Infiltrating Myeloid Cells. Cancers (Basel). 2021; 13(2). PMC: 7825276. DOI: 10.3390/cancers13020165. View